2,2-Dimethyl-3-(toluene-4-sulfonyloxy)-propionic acid | 25255-55-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,2-Dimethyl-3-(toluene-4-sulfonyloxy)-propionic acid
• 英文别名: 2,2-Dimethyl-3-[(4-methylbenzenesulfonyl)oxy]propanoic acid；2,2-dimethyl-3-(4-methylphenyl)sulfonyloxypropanoic acid
• CAS: 25255-55-4
• 化学式: C₁₂H₁₆O₅S
• 分子量: 272.322
• InChiKey: YLJIXBCOSGIURA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  89
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  [Tert-butyl(diphenyl)silyl] 2,2-dimethyl-3-(4-methylphenyl)sulfonyloxypropanoate 在 水 、 N,N-二甲基甲酰胺 作用下， 反应 36.0h， 以86%的产率得到2,2-Dimethyl-3-(toluene-4-sulfonyloxy)-propionic acid
  参考文献：
  名称：

  DMF-mediated deprotection of bulky silyl esters under neutral and fluoride-free conditions

  摘要：

  Bulky TBDPS and TIPS carboxylic esters were efficiently cleaved by a green and mild protocol using only DMF-H2O (20:1) at 70 degrees C. The neutral conditions tolerate various common acid- and base-labile functionalities, including alkyl and aryl silyl ethers. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2015.11.048

文献信息

• [EN] RAPAMYCIN HYDROXYESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] HYDROXYESTERS DE RAPAMICYNE, LEUR PROCEDE D'OBTENTION ET PREPARATIONS PHARMACEUTIQUES LES CONTENANT
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：WO1995028406A1

  公开（公告）日：1995-10-26

  (EN) A compound of structure (I) wherein R1 and R2 are each, independently, hydrogen or -CO(CR3R4)b(CR5R6)dCR7R8R9; R3 and R4 are each, independently, hydrogen, alkyl, alkenyle, alkynyl, trifluoromethyl, or -F; R5 and R6 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, -(CR3R4)fOR10, -CF3, -F, or -CO2R11, or R5 and R6 may be taken together to form X or a cycloalkyl ring that is optionally mono-, di-, or tri-substituted with -(CR3R4)fOR10; R7 is hydrogen, alkyl, alkenyl, alkynyl, -(CR3R4)fOR10, -CF3, -F, or -CO2R11; R8 and R9 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, -(CR3R4)fOR10, -CF3, -F, or -CO2R11, or R8 and R9 may be taken together to form X or a cycloalkyl ring that is optionally mono-, di-, or tri-substituted with -(CR3R4)fOR10; R10 is hydrogen, alkyl, alkenyl, alkynyl, tri-(alkyl)silyl, tri-(alkyl)silylethyl, triphenylmethyl, benzyl, alkoxymethyl, tri-(alkyl)silylethoxymethyl, chloroethyl, or tetrahydropyranyl; R11 is hydrogen, alkyl, alkenyl, alkynyl, or phenylalkyl; X is 5-(2,2-dialkyl)[1,3]dioxanyl, 5-(2-spiro-cycloalkyl)[1,3]dioxanyl, 4-(2,2-dialkyl)[1,3]dioxanyl, 4-(2-spiro-cycloalkyl)[1,3]dioxanyl, 4-(2,2-dialkyl)[1,3]-dioxalanyl, or 4-(2-spiro-cycloalkyl)[1,3]dioxalanyl; b = 0-6; d = 0-6; and f = 0-6 with the proviso that R1 and R2 are both not hydrogen and further provided that either R1 or R2 contains at least one -(CR3R4)fOR10, X, or -(CR3R4)fOR10 substituted cycloalkyl group, or a pharmaceutically acceptable salt thereof which is useful as an immunosuppressive, antiinflammatory, antifungal, antiproliferative, and antitumor agent.(FR) Composé de structure (I) dans lequel: R1 et R2 sont chacun indépendamment hydrogène ou -CO(CR3R4)b(CR5R6)dCR7R8R9; R3 et R4 sont chacun indépendamment hydrogène, alkyle, alcényle, alcynyle, trifluorométhyle ou -F; R5 et R6 sont chacun indépendamment hydrogène, alkyle, alcényle, alcynyle, -(CR3R4)fOR10, -CF3, -F ou -CO2R11, ou bien R5 et R6 peuvent être réunis pour former X ou un cycle cycloalkyle pouvant optionnellement être mono, di ou tri-substitué par -(CR3R4)fOR10; R7 est hydrogène, alkyle, alcényle, alcynyle, -(CR3R4)fOR10, -CF3, -F ou CO2R11; R8 et R9 sont chacun indépendamment hydrogène, alkyle, alcényle, alcynyle, -(R3R4)fOR10, -CF3, -F ou CO2R11, ou bien R8 et R9 peuvent être réunis pour former X ou un cycle cycloalkyle pouvant optionnellement être mono, di ou tri-substitué par -(CR3R4)fOR10; R10 est hydrogène alkyle, alcényle, alcynyle, tri-(alkyl)silyle, tri-(alkyl)silyléthyle, triphénylméthyle, benzyle, alcoxyméthyle, tri-(alkyl)silyléthoxyméthyle, chloroéthyle, ou tétrahydropyranyle; R11 est hydrogène alkyle, alcényle, alcynyle ou phénylalkyle; X est 5-(2,2-dialkyl)[1,3]dioxanyle, 5-(2-spiro-cycloalkyl)[1,3]dioxanyle, 4(2,2-dialkyl)[1,3]dioxanyle, 4(2-spiro-cycloalkyl)[1,3]dioxanyle, 4(2,2-dialkyl)[1,3]dioxalamyle, 4(2-spiro-cycloalkyl)[1,3]dioxalamyle; b = 0-6; d = 0-6; et f = 0-6 sous réserve que R1 et R2 ne soient ni l'un ni l'autre hydrogène et que R1 et R2 contiennent au moins un -(CR3R4)fOR10, un X ou un groupe cycloalkyle à substitution -(CR3R4)fOR10 ou un de leurs sels pharmaceutiquement acceptables servant d'immunosuppresseur, d'anti-inflammatoire, d'antifongique, d'antiproliférant, et d'antitumoral.

  化合物的结构式为(I)，其中R1和R2各自独立地为氢或-CO(CR3R4)b(CR5R6)dCR7R8R9；R3和R4各自独立地为氢、烷基、烯基、炔基、三氟甲基或-F；R5和R6各自独立地为氢、烷基、烯基、炔基、-(CR3R4)fOR10、-CF3、-F或-CO2R11，或者R5和R6可以结合形成X或者一个环烷基，该环烷基可以选择性地单、双或三取代为-(CR3R4)fOR10；R7为氢、烷基、烯基、炔基、-(CR3R4)fOR10、- 、-F或-CO2R11；R8和R9各自独立地为氢、烷基、烯基、炔基、-(CR3R4)fOR10、- 、-F或-CO2R11，或者R8和R9可以结合形成X或者一个环烷基，该环烷基可以选择性地单、双或三取代为-(CR3R4)fOR10；R10为氢、烷基、烯基、炔基、三(烷基)硅烷基、三(烷基)硅基乙基、三苯甲基、苄基、烷氧基甲基、三(烷基)硅基乙氧基甲基、氯乙基或四氢吡喃基；R11为氢、烷基、烯基、炔基或苯基烷基；X为5-(2,2-二烷基)[1,3]二氧杂环己烷基、5-(2-螺环烷基)[1,3]二氧杂环己烷基、4-(2,2-二烷基)[1,3]二氧杂环己烷基、4-(2-螺环烷基)[1,3]二氧杂环己烷基、4-(2,2-二烷基)[1,3]二氧杂丙烷基或4-(2-螺环烷基)[1,3]二氧杂丙烷基；b = 0-6；d = 0-6；f = 0-6，条件是R1和R2均不为氢，并且R1或R2中至少含有一个-(CR3R4)fOR10、X或-(CR3R4)fOR10取代的环烷基，或其药学上可接受的盐，用作免疫抑制剂、抗炎症、抗真菌、抗增殖和抗肿瘤剂。
• Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US11053235B2

  公开（公告）日：2021-07-06

  The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

  该申请描述了可用于治疗或预防 HBV 感染或 HBV 引起的疾病，特别是 HBV 慢性感染或 HBV 慢性感染引起的疾病的二氢嘧啶衍生物，以及其在制药或医疗方面的应用。
• RAPAMYCIN HYDROXYESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0763039A1

  公开（公告）日：1997-03-19
• DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US20200048242A1

  公开（公告）日：2020-02-13

  The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.
• HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
  申请人：Janssen Pharmaceutica NV

  公开号：US20200172532A1

  公开（公告）日：2020-06-04

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.